INTRODUCTION
using the FRET-labeled peptide assay (46). Cytotoxicity of combined agents was monitored in 217 parallel by Cell-Titer Blue staining. Concentration-response curves were used to assess the 218 degree of antagonism, additivity, or synergy at the 50, 75, or 90% effective level. Combination 219 effects were analyzed using in-house software to determine combination indices and 95% 220 confidence intervals, applying the definition of Loewe's synergy cited by Chou (10). Combination studies with ribavirin were carried out essentially as described previously, using 239 Permeability Assay (PAMPA), as well as the cell-based Caco-2 cell model. PAMPA permeability 253 assays were conducted in triplicate with 100 μM compound at room temperature for 4 h using 254 pION © lipid solution, at pH 7.4 and 5.5. Caco-2 cells (ATCC) were seeded at 80,000 cells/cm 2 on 255 a 24-well polycarbonate filter membrane and incubated at 37°C with 5% CO 2 and 95% relative 256 humidity for approximately 21 days, with medium changes every 2 days. Culture medium 257 consisted of DMEM with 10% FBS, 1% nonessential amino acids, 1% L-glutamine, 100 U/ml 258 penicillin-G, and 100 µg/ml streptomycin. The assay was performed at pH 7.4 using Hank's 259 balanced salt solution containing 10 mM HEPES as transport medium. Studies were initiated by 260 adding a buffer-containing compound to either the apical (A-to-B transport) or basolateral (B-261 to-A transport) side of the monolayer, and incubating for 2 h at 37°C. Compound transport was 262 determined by liquid scintillation counting. Permeability coefficients (Pc) were determined 263 using the equation: Pc = dA/(dt·S·C 0 ), where dA/dt is the flux of test compound across the 264 monolayer (nmol/sec), S is the surface area of the cell monolayer (0.33 cm 2 ), and C 0 is the initial 265 concentration (μM) in the donor compartment. 266
In vitro metabolic stability/clearance was determined from duplicate 96-well reactions 267 containing liver microsomes isolated from rat (Sprague-Dawley; BD Biosciences, Woburn, MA), 268 dog (beagle; BD Biosciences), human (pooled samples; BD Biosciences), and monkey 269 (cynomolgus; BD Biosciences). Assays contained 0.5 µM compound, 1% acetonitrile, 1 mg/ml 270 protein, 100 mM potassium phosphate buffer pH7.4, and 6.7 mM magnesium chloride. were determined (Table 1 ). These in vitro potencies were benchmarked against the NS3 PI VX-332 950 (Table 1) Table 2 ). 376 Antiviral activity in cell culture. The activity of ASV against HCV RNA replication was measured 377 using replicons representing the most clinically pertinent genotypes, 1a and 1b, as well as the 378 genotype 2a JFH-1 strain (51). In addition, its effects against hybrid replicons encoding the NS3 379 protease domain representing genotypes 2b, 3a, or 4a were also monitored. Inhibition of HCV 380 RNA replication by ASV was monitored using a luciferase reporter assay; however, comparable 381 inhibitory effects could be determined by directly measuring HCV RNA or protein expression 382 (data not shown) (36). A summary of ASV EC 50 values generated using these assays is shown in 383 (Table 3) . 389 ASV specificity was examined in different cell culture systems. ASV demonstrated no significant 390 activity against BVDV, a pestivirus that is closely related to flaviviruses (48), and other RNA 391 viruses at concentration exceeding 10 µM (Table 4) The results showed a mixture of additive to synergistic effects for rIFNα, as determined from 406 the combination indices (Table 5 ). Additive to synergistic effects were also observed for 407 daclatasvir (synergistic/additive) and NS5B inhibitors (additive or synergistic additive) in two-408 drug combination studies (data shown in Supplementary Tables 1-3 Fig. 1) . 421
In vitro permeability, metabolic stability, and serum protein binding. The permeability of ASV 422 was examined using a PAMPA permeability model and the cell-based Caco-2 bi-directional 423 permeability assay. The Pc values for the NS3 PI in the PAMPA permeability model were >473 424 nm/sec (pH 5.5) and >492 nm/sec (pH 7.4), similar to those of compounds that exhibit good 425 (>80%) absorption in humans. In the Caco-2 cell bi-directional permeability assay, ASV 426 permeability was dependent on the initial drug concentration; (B-A)/(A-B) efflux ratios greater 427 than unity (~31-fold at 5 µM and ~3-fold at 25 µM) were calculated, suggesting that it is a 428 substrate of efflux transporters such as P-glycoprotein (Table 6) . 429
The rate of metabolism of ASV was evaluated in NADPH-fortified liver microsomes of various 430 species. Using the rates of loss of parent compound at 0.5 µM, the predicted hepatic intrinsic 431 clearance (CL h,int ) values were 13.3, 13.3, 31.7, and 8.5 ml/min/kg for rat, dog, monkey, and ASV serum protein binding was assessed across species by equilibrium dialysis, while the direct 439 effect of human serum binding on its antiviral activity was also examined in a replicon cell-440 based assay. In protein binding assays, ASV (10 µM) was 98.8 ± 0.5% bound to human serum 441 protein and 97.2-98.8% bound to serum proteins in the animal species studied (rat, dog, and 442 cynomolgus monkey). Additionally, protein binding of the compound (0.5, 3, and 10 µM) was 443 determined in the replicon assay medium (containing 4% FBS) and found to be 77.6 ± 1.5, 76.0 444 ± 4.8, and 68.1 ± 1.1% bound at each of the concentrations evaluated, respectively. When the 445 replicon buffer contained 40% human serum, ASV protein binding was increased to 97.4 ± 0.66, 446 97.7 ± 0.31, and 97.6 ± 0.54% bound at 0.5, 3, and 10 µM, respectively. Supplementation of 447 40% human serum to an HCV genotype 1b replicon assay resulted in a loss in ASV potency of 448 approximately 6.5-fold. This loss in EC 50 value compared with a 6.8-fold loss observed for VX-449
(data not shown). 450
In vivo plasma and tissue exposures across species. Plasma and liver concentration, as well as 451 that in other organs, were assessed in mouse, rat, dog and monkey, with results summarized in 452 Table 7 . FVB mice were dosed orally (PO) with ASV, and drug exposure was monitored over 24 453 h. Liver concentrations in all animals were highly elevated over those in plasma (Table 7) 
DISCUSSION

478
ASV is a linear peptide mimetic HCV NS3 PI, discovered using a structure-based drug design 479 approach to replace the carboxylate moiety of ciluprevir derivatives, with a proprietary P1' 480 acylsulfonamide cyclopropyl moiety with the aim of significantly enhancing potency (Fig. 1) (7) . 481
Comprehensive profiling has demonstrated that ASV is a highly selective inhibitor of HCV 482 NS3/4A protease complex enzymatic activity, effectively inhibiting four major HCV genotype 483 classes (Table 1) . It is most active against proteases representing genotype 1, the genotype with 484 the highest unmet medical need, while isolates representing genotypes 2 and 3 were the least 485 susceptible to inhibition. The reduced activity against genotype 3 was anticipated, since the 486 reported salt bridge that forms between the charged NS3 amino acid residues R155 and D168 487 in genotypes 1, 4, 5, and 6 (49), stabilizing the interaction of the bulky P2 moiety of ASV with 488 the enzyme, would not form. This is a consequence of the NS3-168 amino acid being a 489 glutamine in genotype 3a. Replacement of the charged D168 for neutral residues, predicted to 490 weaken or destroy the 155:168 salt bridge, results in a reduced susceptibility to ASV (30) . For 491 the genotype 2 subtype, the residue at NS3-122 is either a lysine (genotype 2a) or arginine 492 (genotype 2b). This residue is close to charged residues D168 and R123, and replacement of the 493 neutral serine by arginine could lead to conformational changes affecting the binding of ASV 494 and NS3 PIs with similar bulky P2 moieties (49). 495
Kinetic characterization of ASV against HCV genotype 1a and 1b NS3/4A protease complexes in 496 homogeneous in vitro assays indicated that it is a classic competitive inhibitor with K i values in 497 the picomolar range. The classic competitive inhibition curve, as calculated from a Lineweaver-498
Burk plot (Fig. 2) , confirmed that ASV is a non-covalent, single-step competitive inhibitor rather 499 on October 16, 2017 by guest http://aac.asm.org/ Downloaded from 25 than a covalent (telaprevir and boceprevir) or non-covalent (danoprevir), two-step slow 500 reversible inhibitor (40). In theory, NS3 PIs exhibiting slower off-rates from the enzyme could 501 confer greater efficacy in patients and result in lower doses and less frequent dosing. However, 502 the off-rate would need to be longer than the drug exposure half-life to have impact in 503 patients. Since telaprevir and boceprevir are administered 3 times daily at high doses and 504 danoprevir appears likely to require boosting with ritonavir to achieve twice-daily 505 administration (18), it is unclear whether the observed in vitro slow off-rates confer any 506 advantage over ASV. However, single-and multiple-ascending dose monotherapy clinical 507 studies with ASV indicated rapid robust responses at lower doses than reported for telaprevir, 508 boceprevir, or danoprevir (37). 509 ASV was shown to be highly specific for the HCV NS3 serine protease, demonstrating 510 micromolar activity against the closely related GBV-B NS3 protease (Table 2) . Furthermore, it 511 exhibited little or no activity against a panel of human serine or cysteine proteases including 512 elastase, the most homologous of these proteases. The selectivity index calculated for ASV was 513 significantly greater than calculated for VX-950 (telaprevir), which demonstrated 514 submicromolar to low micromolar activities against a number of human serine and cysteine 515 proteases. The reported exposure of telaprevir administered to HCV-infected patients (C max , 3.5 516 µg/ml; C min , 2 µg/ml) is higher than the observed intrinsic potencies against some of these 517 human proteases. This may have potential implications with respect to off-target side effects 518 such as the skin orders (rash and pruritus) reported with telaprevir (50). The reduced selectivity 519 Assessment of the in vitro permeability properties of ASV indicated that the compound should 548 be readily absorbed. However, this absorption may be influenced by efflux transporters such as 549 P-glycoprotein (Table 6 ) and lead to variable drug exposure. ASV was predicted to exhibit low to 550 intermediate metabolic clearance, with calculated human hepatic clearance being more similar 551 to that predicted for dogs than for rats or monkeys. While ASV was shown to be highly bound 552 to serum proteins, its intrinsic potency was not attenuated in an NS3/4A protease enzyme 553 assay supplemented with albumin to a concentration equivalent to that in human serum (data 554 not shown). However, modest attenuation of anti-NS3 protease activity was observed in an 555 HCV genotype 1b replicon assay supplemented with 40% human serum. This fold-loss in 556 potency is comparable with values obtained for other NS3 PIs. 557
The exposure profile of ASV across four different animal species (mouse, rat, dog, and monkey) 558 revealed its hepatotropic disposition in all tested species, as indicated by a high exposure in 559 liver versus plasma (Table 7) . Compound exposure in other tissues examined, such as brain or 560 spleen, was comparable to or less than that observed in plasma. Subsequent studies indicated 561 that there was active uptake of ASV into the hepatocyte and elimination via the bile across 562 species (unpublished results), suggesting that the compound was enriched in hepatocytes. 
